Keywords
Carcinoma, Renal Cell ×
Eligibility Determination ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

41 Search results.

Eligibility Carcinoma, Renal Cell NCT01441388

- 10/28/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.; ODM derived from: https://clinicaltrials.gov/show/NCT01441388

Eligibility Carcinoma, Renal Cell NCT01107509

- 10/17/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers; ODM derived from: https://clinicaltrials.gov/show/NCT01107509

Eligibility Renal Cell Carcinoma NCT01984242

- 7/1/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01984242

Eligibility Renal Cell Carcinoma NCT02399124

- 7/1/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Post Marketing Surveillance for ICE-SENSE™3 a Cryotherapy Treatment of Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02399124

DC/RCC Fusion Vaccine in Renal Cell Carcinoma NCT01441765 - Eligibility

- 5/21/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study of PD-1 Blockade Alone or In Conjunction With the Dendritic Cell (DC)/Renal Cell Carcinoma (RCC) Fusion Cell Vaccination; ODM derived from: https://clinicaltrials.gov/show/NCT01441765

Eligibility Metastatic Renal Cell Carcinoma NCT02398552

- 5/11/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.; ODM derived from: https://clinicaltrials.gov/show/NCT02398552

Eligibility Metastatic Renal Cell Carcinoma NCT02330783

- 5/11/19 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02330783

Eligibility ccRCC NCT02293980

- 2/23/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02293980

Eligibility Carcinoma, Renal Cell NCT02454478

- 2/20/19 - 1 form, 2 itemgroups, 35 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Lenvatinib in Combination With Everolimus in Patients With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC); ODM derived from: https://clinicaltrials.gov/show/NCT02454478

Eligibility Carcinoma, Renal Cell NCT02497599

- 2/20/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Intraoperative Dual-modality Imaging in Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02497599

Eligibility Carcinoma, Renal Cell NCT02386111

- 2/20/19 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02386111

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

- 1/17/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib; ODM derived from: https://clinicaltrials.gov/show/NCT01514448